Advertisement

5 Cancer Tests and Treatments with Little or No Value — Physician’s First Watch

Medical News |
October 30, 2013

5 Cancer Tests and Treatments with Little or No Value

By Joe Elia

The American Society of Clinical Oncology has identified a second group of commonly used tests and treatments in cancer medicine that have little or no benefit. The list, part of the American Board of Internal Medicine's "Choosing Wisely" initiative, appears in the Journal of Clinical Oncology.

Briefly, here are this year's "top five" items:

  • Don't give antiemetics to patients starting chemotherapies that have low-to-moderate potential for causing symptoms.

  • In treating metastatic breast cancer, avoid combination chemotherapy unless the patient's cancer burden needs to be reduced quickly.

  • Avoid PET scanning in routine follow-up unless there's "high-level" evidence that the imaging will improve outcomes.

  • Don't do PSA testing in asymptomatic men when life expectancy is under 10 years.

  • Don't use therapy targeted against a specific genetic aberration unless the patient has specific biomarkers that predict effective response.

Reader Comments (1)

H BLOOM Physician, Family Medicine/General Practice

This is good

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement